Xuanqi An1, Jingang Yang1, Kefei Dou1, Yuejin Yang1. 1. Department of Cardiology, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 167, North Lishi Road, Xicheng District, Beijing 100037, China.
Abstract
BACKGROUND: The prognostic significance of CTO in the non-IRA in patients with AMI has been under dispute. Relevant long-term follow-up studies are lacking. Hypothesis. CTO in the non-IRA is an independent predictor of poor long-term prognosis in patients with AMI. METHODS: We prospectively enrolled 2336 patients with AMI who received emergent percutaneous coronary intervention successfully from January 2006 to May 2011. Our primary endpoints included death from cardiovascular causes, recurrent myocardial infarction, stroke, and target-vessel revascularization. We adopted Cox regression analysis adjusted for confounders to analyze the impact of CTO in the non-IRA on long-term mortalities. RESULTS: We identified 628 (27.6%) subjects with CTO in the non-IRA among 2282 AMI patients. After a mean follow-up duration of 134.3 months, we found the CTO group had significantly higher MACCE rate than the group without CTO (30.4% versus 24.3%, P=0.004). CTO in the non-IRA independently predicted 11-year MACCE in the male AMI subgroup (hazard ratio 1.28, 95% confidence interval 1.06 to 1.54, P=0.01) and in the male NSTEMI subgroup (hazard ratio 1.53, 95% confidence interval 1.09 to 2.15, P=0.02). In the CTO group, three-vessel disease independently predicted 11 year MACCE (hazard ratio 2.05, 95% confidence interval 1.29 to 3.28, P=0.002). CONCLUSIONS: Our long-term observational study supported the association between CTO in the non-IRA and poorer prognosis in AMI patients undergoing primary PCI. We identified the group with the three-vessel disease as a high-risk subgroup in patients with CTO in the non-IRA.
BACKGROUND: The prognostic significance of CTO in the non-IRA in patients with AMI has been under dispute. Relevant long-term follow-up studies are lacking. Hypothesis. CTO in the non-IRA is an independent predictor of poor long-term prognosis in patients with AMI. METHODS: We prospectively enrolled 2336 patients with AMI who received emergent percutaneous coronary intervention successfully from January 2006 to May 2011. Our primary endpoints included death from cardiovascular causes, recurrent myocardial infarction, stroke, and target-vessel revascularization. We adopted Cox regression analysis adjusted for confounders to analyze the impact of CTO in the non-IRA on long-term mortalities. RESULTS: We identified 628 (27.6%) subjects with CTO in the non-IRA among 2282 AMI patients. After a mean follow-up duration of 134.3 months, we found the CTO group had significantly higher MACCE rate than the group without CTO (30.4% versus 24.3%, P=0.004). CTO in the non-IRA independently predicted 11-year MACCE in the male AMI subgroup (hazard ratio 1.28, 95% confidence interval 1.06 to 1.54, P=0.01) and in the male NSTEMI subgroup (hazard ratio 1.53, 95% confidence interval 1.09 to 2.15, P=0.02). In the CTO group, three-vessel disease independently predicted 11 year MACCE (hazard ratio 2.05, 95% confidence interval 1.29 to 3.28, P=0.002). CONCLUSIONS: Our long-term observational study supported the association between CTO in the non-IRA and poorer prognosis in AMI patients undergoing primary PCI. We identified the group with the three-vessel disease as a high-risk subgroup in patients with CTO in the non-IRA.
Authors: Abdul M Mozid; Shah Mohdnazri; Nilanka N Mannakkara; Nicholas M Robinson; Rohan Jagathesan; Jeremy W Sayer; Rajesh K Aggarwal; Gerald J Clesham; Reto A Gamma; Kare H Tang; Paul A Kelly; John R Davies Journal: J Invasive Cardiol Date: 2014-01 Impact factor: 2.022
Authors: Stephen A O'Connor; Philippe Garot; Francesca Sanguineti; Loes P Hoebers; Thierry Unterseeh; Hakim Benamer; Bernard Chevalier; Thomas Hovasse; Marie-Claude Morice; Thierry Lefèvre; Yves Louvard Journal: Am J Cardiol Date: 2015-04-06 Impact factor: 2.778
Authors: Truls Råmunddal; Loes P Hoebers; José P S Henriques; Christian Dworeck; Oskar Angerås; Jacob Odenstedt; Dan Ioanes; Göran Olivecrona; Jan Harnek; Ulf Jensen; Mikael Aasa; Per Albertsson; Hans Wedel; Elmir Omerovic Journal: JACC Cardiovasc Interv Date: 2016-08-08 Impact factor: 11.195
Authors: Joëlle Elias; Ivo M van Dongen; Truls Råmunddal; Peep Laanmets; Erlend Eriksen; Martijn Meuwissen; H Rolf Michels; Matthijs Bax; Dan Ioanes; Maarten Jan Suttorp; Bradley H Strauss; Emanuele Barbato; Koen M Marques; Bimmer E P M Claessen; Alexander Hirsch; René J van der Schaaf; Jan G P Tijssen; José P S Henriques; Loes P Hoebers Journal: Heart Date: 2018-02-20 Impact factor: 5.994
Authors: Albert Ariza-Solé; Luis Teruel; Andrea di Marco; Victòria Lorente; José C Sánchez-Salado; Guillermo Sánchez-Elvira; Rafael Romaguera; Josep Gómez-Lara; Joan A Gómez-Hospital; Angel Cequier Journal: Rev Esp Cardiol (Engl Ed) Date: 2014-02-13